Featured Research

from universities, journals, and other organizations

Researchers Test Nanoparticle To Treat Cardiovascular Disease In Mice

Date:
June 15, 2009
Source:
University of California - Santa Barbara
Summary:
Scientists and engineers have developed a nanoparticle that can attack plaque -- a major cause of cardiovascular disease.

An image of a multifunctional micelle designed by research team at UCSB.
Credit: Peter Allen, UCSB College of Engineering

Scientists and engineers at UC Santa Barbara and other researchers have developed a nanoparticle that can attack plaque –– a major cause of cardiovascular disease. The new development is described in a recent issue of the Proceedings of the National Academy of Sciences.

The treatment is promising for the eventual development of therapies for cardiovascular disease, which is blamed for one third of the deaths in the United States each year. Atherosclerosis, which was the focus of this study, is one of the leading causes of cardiovascular disease. In atherosclerosis, plaque builds up on the walls of arteries and can cause heart attack and stroke.

"The purpose of our grant is to develop targeted nanoparticles that specifically detect atherosclerotic plaques," said Erkki Ruoslahti, distinguished professor at the Burnham Institute for Medical Research at the University of California, Santa Barbara. "We now have at least one peptide, described in the paper, that is capable of directing nanoparticles to the plaques."

The nanoparticles in this study are lipid-based collections of molecules that form a sphere called a micelle. The micelle has a peptide, a piece of protein, on its surface, and that peptide binds to the surface of the plaque.

Co-author Matthew Tirrell, The Richard A. Auhll Professor and dean of UCSB's College of Engineering, specializes in lipid-based micelles. "This turned out to be a perfect fit with our targeting technology," said Ruoslahti.

To accomplish the research, the team induced atherosclerotic plaques in mice by keeping them on a high-fat diet. They then intravenously injected these mice with the micelles, which were allowed to circulate for three hours.

"One important element in what we did was to see if we could target not just plaques, but the plaques that are most vulnerable to rupture," said Ruoslahti. "It did seem that we were indeed preferentially targeting those places in the plaques that are prone to rupture."

The plaques tend to rupture at the "shoulder," where the plaque tissue meets the normal tissue. "That's also a place where the capsule on the plaque is the thinnest," said Ruoslahti. "So by those criteria, we seem to be targeting the right places."

Tirrell added:"We think that self-assembled micelles (of peptide amphiphiles) of the sort we have used in this work are the most versatile, flexible nanoparticles for delivering diagnostic and therapeutic biofunctionality in vivo. The ease with which small particles, with sufficiently long circulation times and carrying peptides that target and treat pathological tissue, can be constructed by self-assembly is an important advantage."

Ruoslahti said that UCSB's strength in the areas of materials, chemistry, and bioengineering facilitated this research. He noted that he and Tirrell have been close collaborators.

The work was funded by a grant from the National Heart, Lung and Blood Institute of the National Institutes of Health.

In addition to Ruoslahti and Tirrell, the article, "Targeting Atherosclerosis Using Modular, Multifunctional Micelles," was authored by David Peters of the Burnham Institute at UCSB and the Biomedical Sciences Graduate Group at UC San Diego; Mark Kastantin of UCSB's Department of Chemical Engineering; Venkata Ramana Kotamraju of the Burnham Institute at UCSB; Priya P. Karmali of the Cancer Research Center, Burnham Institute for Medical Research in La Jolla; and Kunal Gujraty of the Burnham Institute at UCSB.


Story Source:

The above story is based on materials provided by University of California - Santa Barbara. Note: Materials may be edited for content and length.


Journal Reference:

  1. David Peters, Mark Kastantin, Venkata Ramana Kotamraju, Priya P. Karmali, Kunal Gujraty, Matthew Tirrell, and Erkki Ruoslahti. Targeting atherosclerosis by using modular, multifunctional micelles. Proceedings of the National Academy of Sciences, 2009; DOI: 10.1073/pnas.0903369106

Cite This Page:

University of California - Santa Barbara. "Researchers Test Nanoparticle To Treat Cardiovascular Disease In Mice." ScienceDaily. ScienceDaily, 15 June 2009. <www.sciencedaily.com/releases/2009/06/090604155619.htm>.
University of California - Santa Barbara. (2009, June 15). Researchers Test Nanoparticle To Treat Cardiovascular Disease In Mice. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2009/06/090604155619.htm
University of California - Santa Barbara. "Researchers Test Nanoparticle To Treat Cardiovascular Disease In Mice." ScienceDaily. www.sciencedaily.com/releases/2009/06/090604155619.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins